Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM589XM)

• Drug Name: S-19528 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Eating disorder	6B82	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10393643
  TTD Drug ID: DM589XM

Molecule-Related Drug Atlas

Drug(s) Targeting Neuropeptide Y receptor type 5 (NPY5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CGP71683A	DMRYC08	Obesity	5B81	Discontinued in Phase 3	[2]
Velneperit	DMROSHN	Obesity	5B81	Discontinued in Phase 2	[3]
S-234462	DM80P4U	Obesity	5B81	Discontinued in Phase 1	[3]
Axovan-3	DM1JN6A	Eating disorder	6B82	Discontinued in Phase 1	[1]
FR-79620	DMXR287	Diabetic complication	5A2Y	Preclinical	[4]
GW-594884A	DMHUD27	Obesity	5B81	Preclinical	[4]
NPY5RA-972	DMXUCSN	Obesity	5B81	Preclinical	[4]
RWJ-49815	DMUGZMO	Fungal infection	1F29-1F2F	Terminated	[1]
AR-129330	DMUSYKG	Discovery agent	N.A.	Investigative	[5]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]	DMKANOH	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Neuropeptide Y receptor type 1 (NPY1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NEUROPEPTIDE-Y	DMINQP1	N. A.	N. A.	Phase 2	[7]
H-409/22	DMYJ9CF	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[8]
PD-160170	DMB9Z4C	Heart disease	BA41-BA42	Preclinical	[4]
GI-264879A	DM25N8B	Obesity	5B81	Preclinical	[4]
SR 120819A	DMETDFM	Eating disorder	6B82	Terminated	[9]
BIBP 3226	DMYBR9D	Hypertension	BA00-BA04	Terminated	[10]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[11]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	DMKH8PF	Discovery agent	N.A.	Investigative	[12]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DM4SWQA	Discovery agent	N.A.	Investigative	[12]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuropeptide Y receptor type 1 (NPY1R)	TTRK9JT	NPY1R_HUMAN	Antagonist	[1]
Neuropeptide Y receptor type 5 (NPY5R)	TTY6EWA	NPY5R_HUMAN	Antagonist	[1]

References

• [1] Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
• [2] Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
• [3] Clinical pipeline report, company report or official report of Shionogi (2011).
• [4] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [5] Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
• [6] Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.
• [7] 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
• [8] In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
• [9] SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
• [11] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [12] Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.